Get the Stockscreener App
3.52
5.07%
0.17
Pre-market:
3.52
Abvc Biopharma Inc stock is traded at $3.52, with a volume of 235.25K.
It is up +5.07% in the last 24 hours and up +91.30% over the past month.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
See More
Previous Close:
$3.35
Open:
$3.39
24h Volume:
235.25K
Relative Volume:
0.56
Market Cap:
$59.78M
Revenue:
$152.40K
Net Income/Loss:
$-10.52M
P/E Ratio:
-1.4119
EPS:
-2.4931
Net Cash Flow:
$-4.26M
1W Performance:
+0.28%
1M Performance:
+91.30%
6M Performance:
+550.41%
1Y Performance:
+326.15%
1-Day Range:
$3.35
$3.60
1-Week Range:
$3.28
$3.92
52-Week Range:
$0.40
$5.48
Abvc Biopharma Inc Stock (ABVC) Company Profile
Name
Abvc Biopharma Inc
Sector
Industry
Phone
510-668-0881
Address
44370 OLD WARM SPRINGS BLVD., FREMONT
Compare ABVC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABVC
Abvc Biopharma Inc
|
3.52 | 59.61M | 152.40K | -10.52M | -4.26M | -2.4931 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Abvc Biopharma Inc Stock (ABVC) Latest News
ABVC BioPharma Inc. Stock Analysis and ForecastFree Advanced Stock Screener Access - jammulinksnews.com
What drives ABVC BioPharma Inc. stock priceAccelerated wealth expansion - PrintWeekIndia
What analysts say about ABVC BioPharma Inc. stockFree Consultation - PrintWeekIndia
What makes ABVC BioPharma Inc. stock attractive to long term investorsValue Pick Scanner - Newser
Is ABVC BioPharma Inc. stock a growth or value playSafe Entry High Exit Alerts - Newser
Is ABVC BioPharma Inc. a good long term investmentFree Technical Analysis Support - jammulinksnews.com
ABVC BioPharma Records $100,000 Licensing Milestone From ForSeeCon, Strengthening Eye Health Program - Yahoo Finance
What makes ABVC BioPharma Inc. stock price move sharplySteady Profit Stock Forecasts - Newser
Why ABVC BioPharma Inc. stock attracts strong analyst attentionDaily Gain Forecast - Newser
How ABVC BioPharma Inc. stock performs during market volatilityFree Exclusive Access to Stock Gurus - Newser
ABVC BioPharma Soars 16%—Is This the Breakout Biotech Investors Have Been Waiting For? - AInvest
ABVC BioPharma Receives $150K Milestone From AiBtl, Bringing Total Licensing Revenue to $846K Across Strategic Partnerships - Yahoo Finance
ABVC BioPharma CEO Dr. Uttam Patil Recognized Among Elite Indian-Origin CEOs Making Global Impact in Science and Technology - StreetInsider
ABVC BioPharma Converts Strategic Note Into Equity in AiBtl BioPharma; Commits to Up to $20 Million in Total Investment - Yahoo Finance
ABVC BioPharma's Affiliate OncoX Acquires Lycopenoid Platform to Strengthen Oncology Portfolio - citybuzz -
ABVC BioPharma Expands Oncology Portfolio as Affiliate OncoX Acquires Patented Lycopenoid Platform Valued at $4.06 Million - The Globe and Mail
ABVC BioPharma Shareholders Approve Key Proposals - TipRanks
ABVC BioPharma Announces Board Approval of Share Dividend Showing Confidence in Subsidiary Growth and Long-Term Shareholder Value - Yahoo Finance
ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Up 40.0% in May - Defense World
3 Top Growth Stocks to Buy in the Second Half of 2025 - The Globe and Mail
ABVC BioPharma Files $100 Million Mixed Shelf - marketscreener.com
ABVC BioPharma Regains Nasdaq Minimum Bid Price Compliance - Yahoo Finance
ABVC BioPharma Secures Japanese Patent for Botanical Depression Treatment - citybuzz -
ABVC BioPharma Secures Japanese Patent for Its Natural MDD Treatment Candidate ABV-1504 - Yahoo Finance
ABVC BioPharma Announces First Quarter 2025 Financial Results and Strategic Planning for AI-Driven Agricultural Project in Taiwan - Yahoo Finance
ABVC BIOPHARMA, INC. SEC 10-Q Report - TradingView
ABVC BioPharma and AiBtl BioPharma's Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
UPDATE: ABVC BioPharma Announces 2024 Financial Results - Yahoo Finance
ABVC BioPharma Reports Strong Financial Growth - TipRanks
ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements - marketscreener.com
ABVC BioPharma Announces 2024 Financial Results - Yahoo Finance
ABVC BIOPHARMA, INC. SEC 10-K Report - TradingView
Abvc Biopharma Inc Stock (ABVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.87%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):